Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
IBB vs MOAT: how they differ
IBB and MOAT hold 0% of their weight in the same names, and IBB returned more over the year.
iShares Biotechnology ETF and VanEck Morningstar Wide Moat ETF.
What they hold in common
By the books each fund has filed, IBB and MOAT hold 0% of their money in the same securities at the same weight.
| Only in IBB | Only in MOAT |
|---|---|
| Vertex Pharmaceuticals, Inc. 8.09% | Masco Corp 2.96% |
| Amgen, Inc. 7.84% | Kenvue Inc 2.59% |
| Gilead Sciences, Inc. 6.85% | Airbnb Inc 2.56% |
| Regeneron Pharmaceuticals, Inc. 4.91% | Palo Alto Networks Inc 2.51% |
| Argenx SE 3.76% | Brown-Forman Corp 2.49% |
| Alnylam Pharmaceuticals, Inc. 3.12% | Charles Schwab Corp/The 2.45% |
| Natera, Inc. 2.89% | NVIDIA Corp 2.45% |
| Revolution Medicines, Inc. 2.78% | Datadog Inc 2.44% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| IBB iShares Biotechnology ETF | MOAT VanEck Morningstar Wide Moat ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | VanEck |
| What it is | Biotechnology | Morningstar Wide Moat |
| Total return, 1 year | +41.5% | +11.3% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +24.0 pts | −6.2 pts |
| Expense ratio | 0.44% | 0.46% |
| Already in the S&P 500 | 35.6% | 91.6% |
| Holdings | 248 | 55 |
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
MOAT in plain words
MOAT is an index equity fund tracking the Morningstar Wide Moat. Over the year to Sep 11, 2026 it returned +11.3% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.46% a year. By its holdings filed for Jun 30, 2026, 92% of the fund by weight is stocks the S&P 500 also holds, across 55 positions, with the top ten at 25.3%. It sat 5.7% below its high of Aug 27, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, IBB or MOAT?
- In the year to Sep 12, 2026, with distributions reinvested, IBB returned +41.5% and MOAT returned +11.3%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, IBB or MOAT?
- IBB charges 0.44% a year and MOAT charges 0.46%, so IBB is cheaper. Fees come from each fund's prospectus.
- How much do IBB and MOAT overlap with the S&P 500?
- By their latest filed holdings, 36% of IBB and 92% of MOAT by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IBB against MOAT, data as of Sep 12, 2026. https://etfiq.com/compare/any/IBB-MOAT Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources